Clinical Analysis of Lamivudine Combined with Low-Dose Hepatitis B Immune Globulin to Prevent HBV Reinfection after Liver Transplantation_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 YUANWei-sheng , GONGLin , LIUPeng , JIAOXue-li , GUODa-wei , WANGPeng

Department of Hepatobiliary Surgery, No. 401 Hospital of Chinese PLA, Qingdao 266071, Shandong Province, China;

Corresponding?author：

YUANWei-sheng, Email: yuanweisheng401@126.com

Keywords：

Liver transplantation; Hepatitis B virus; Hepatitis B immune globulin; Lamivudine

DOI：

10.7507/1007-9424.20150119

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the efficacy of lamivudine combined with low-dose hepatitis B immune globulin to prevent HBV reinfection after liver transplantation. Methods The clinical data of 76 cases of HBV-related liver disease after liver transplantation using lamivudine combined with low-dose hepatitis B immune globulin to prevent HBV re-infection were retrospectively analyzed, and the HBV re-infection risk factors were analyzed. Results Seventy-six patients' HBsAg became negative after liver transplantation, HBV re-infect in 9 cases.The re-infection rate was 9.2% (7/76) and 11.8% (9/76), respectively, in 1-year and 2-year after liver transplantation. Conclusions Lamivudine combined with low-dose hepatitis B immune globulin after liver transplantation can be effective preventing re-infection with HBV.HBeAg positive and HBV-DNA positive before liver transplantation is risk factors of HBV re-infection.

Citation： YUANWei-sheng, GONGLin, LIUPeng, JIAOXue-li, GUODa-wei, WANGPeng. Clinical Analysis of Lamivudine Combined with Low-Dose Hepatitis B Immune Globulin to Prevent HBV Reinfection after Liver Transplantation. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(4): 451-454. doi: 10.7507/1007-9424.20150119 Copy

1.	Jiang L, Yan LN.Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.World J Gastroenterol, 2010, 16(20):2468-2475.
2.	Mehrabi A, Esmaeilzadeh M, Fonouni H, et al.The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.Langenbecks Archi Surg, 2012, 397(5):697-710.
3.	中華醫學會傳染病與寄生蟲病學會分會、肝病學會.病毒性肝炎防治方案.中華傳染病雜志, 2001, 19(1):56-52.
4.	Mazzaferro V, Regalia E, Montalto F, et al.Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis.Primary hepatocellular carcinoma is not a predictor for HBV recurrence.The European Cooperative Study Group on Liver Cancer and Transplantation.Liver, 1996, 16(2):117-122.
5.	李春滿, 李立.肝移植術后乙肝復發的預防和治療.中國普外基礎與臨床雜志, 2004, 5(2):416-417.
6.	白桂芹, 成軍, 劉妍, 等.拉米夫定在肝移植患者抗病毒治療中的應用.世界華人消化雜志, 2004, 12(10):2432-2434.
7.	Maguire D, Heaton ND, Smith HM.Failure of reactivation of hepatitis B after liver transplantation in hepatitis B surface antigen negative, core antibody-positive recipients.Transplantation, 2002, 73(3):481-482.
8.	Bourne EJ, Dienstag JL, Lopez VA, et al.Quantitative analysis of HBV cccDNA from clinical specimens:correlation with clinical an dvirological response during antiviral therapy.J Viral Hepat, 2007, l4(1):55-63.
9.	Mohanty SR, Cotler SJ.Management of hepatitis B in liver transplant patients.J Clin Gastroenterol, 2005, 39(1):58-63.
10.	Perrillo RP, Wright T, Rakela J, et al.A mulficenter United States-Canadian trial to assess lamivudine monotherapy before and afte liver transplantation for chronic hepatitis B.Hepatology, 2001, 33(2):424-432.
11.	李健, 魏憲義, 傅志仁.拉米夫定.乙肝免疫球蛋白防治肝移植術后HBV再感染的功效比較及臨床應用進展.中華肝膽外科雜志, 2007, 13(8):568-570.
12.	Fox AN, Terrault NA.The option of HBIG-free prophylaxis against recurrent HBV.J Hepatol, 2012, 56(5):1189-1197.
13.	Zhu JP, Zhang TL, Li L, et al.Prevention and treatment of hepatitis B recurrence after liver transplantation.Hepatobiliary Pancreat Dis Int, 2003, 2(4):500-503.
14.	Yuan CH, Xiu DR, Jiang B, et al.HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients:ten-year experience.Hepatobiliary Pancreat Dis Int, 2013, 12(2):149-153.
15.	Luo KX, Zhou FY, Liu DL, et al.Simple nucleos(t)ides as HBV prophylaxis regime of post-liver transplantation:Six-year followed up.World J Hepatol, 2010, 2(12):447-450.
16.	Anderson RD, Chinnakotla S, Guo L, et al.Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation:comparison with other HBIG regimens.Clinical Transplantation, 2007, 21(4):510-517.
17.	Angus PW, Patterson SJ, Strasser SI, et al.A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.Hepatology, 2008, 48(5):1460-1466.
18.	Xi ZF, Xia Q.Recent advances in prevention of hepatitis B recurrence after liver transplantation.World J Gastroenterol, 2015, 21(3):829-835.
19.	Marzano A.The prevention of viral recurrence in the long term.Dig Liver Dis, 2009, 41 Suppl 2:S195-S197.
20.	Roche B, Samuel D.Prevention of hepatitis B virus reinfection in liver transplant recipients.Intervirology, 2014, 57(3-4):196-201.
21.	Jiang L, Yan L, Li B, et al.Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin.Am J Transplant, 2010, 10(8):1861-1869.
22.	Marcellin P, Samuel D, Areias J, et al.Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease.Hepatology, 1994, 19(1):6-12.
23.	Yang Y, Zhang Q, Cai CJ, et al.Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.Chin Med J (Engl), 2007, 120(16):1400-1403.
24.	Ueda Y, Marusawa H, Kaido T, et al.Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation.Hepatol Res, 2013, 43(1):67-71.
25.	Chen J, Yi L, Jia JD, et al.Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation:a systematic review.J Gastroenterol Hepatol, 2010, 25(5):872-879.

1. Jiang L, Yan LN.Current therapeutic strategies for recurrent hepatitis B virus infection after liver transplantation.World J Gastroenterol, 2010, 16(20):2468-2475.
2. Mehrabi A, Esmaeilzadeh M, Fonouni H, et al.The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.Langenbecks Archi Surg, 2012, 397(5):697-710.
3. 中華醫學會傳染病與寄生蟲病學會分會、肝病學會.病毒性肝炎防治方案.中華傳染病雜志, 2001, 19(1):56-52.
4. Mazzaferro V, Regalia E, Montalto F, et al.Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis.Primary hepatocellular carcinoma is not a predictor for HBV recurrence.The European Cooperative Study Group on Liver Cancer and Transplantation.Liver, 1996, 16(2):117-122.
5. 李春滿, 李立.肝移植術后乙肝復發的預防和治療.中國普外基礎與臨床雜志, 2004, 5(2):416-417.
6. 白桂芹, 成軍, 劉妍, 等.拉米夫定在肝移植患者抗病毒治療中的應用.世界華人消化雜志, 2004, 12(10):2432-2434.
7. Maguire D, Heaton ND, Smith HM.Failure of reactivation of hepatitis B after liver transplantation in hepatitis B surface antigen negative, core antibody-positive recipients.Transplantation, 2002, 73(3):481-482.
8. Bourne EJ, Dienstag JL, Lopez VA, et al.Quantitative analysis of HBV cccDNA from clinical specimens:correlation with clinical an dvirological response during antiviral therapy.J Viral Hepat, 2007, l4(1):55-63.
9. Mohanty SR, Cotler SJ.Management of hepatitis B in liver transplant patients.J Clin Gastroenterol, 2005, 39(1):58-63.
10. Perrillo RP, Wright T, Rakela J, et al.A mulficenter United States-Canadian trial to assess lamivudine monotherapy before and afte liver transplantation for chronic hepatitis B.Hepatology, 2001, 33(2):424-432.
11. 李健, 魏憲義, 傅志仁.拉米夫定.乙肝免疫球蛋白防治肝移植術后HBV再感染的功效比較及臨床應用進展.中華肝膽外科雜志, 2007, 13(8):568-570.
12. Fox AN, Terrault NA.The option of HBIG-free prophylaxis against recurrent HBV.J Hepatol, 2012, 56(5):1189-1197.
13. Zhu JP, Zhang TL, Li L, et al.Prevention and treatment of hepatitis B recurrence after liver transplantation.Hepatobiliary Pancreat Dis Int, 2003, 2(4):500-503.
14. Yuan CH, Xiu DR, Jiang B, et al.HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients:ten-year experience.Hepatobiliary Pancreat Dis Int, 2013, 12(2):149-153.
15. Luo KX, Zhou FY, Liu DL, et al.Simple nucleos(t)ides as HBV prophylaxis regime of post-liver transplantation:Six-year followed up.World J Hepatol, 2010, 2(12):447-450.
16. Anderson RD, Chinnakotla S, Guo L, et al.Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation:comparison with other HBIG regimens.Clinical Transplantation, 2007, 21(4):510-517.
17. Angus PW, Patterson SJ, Strasser SI, et al.A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.Hepatology, 2008, 48(5):1460-1466.
18. Xi ZF, Xia Q.Recent advances in prevention of hepatitis B recurrence after liver transplantation.World J Gastroenterol, 2015, 21(3):829-835.
19. Marzano A.The prevention of viral recurrence in the long term.Dig Liver Dis, 2009, 41 Suppl 2:S195-S197.
20. Roche B, Samuel D.Prevention of hepatitis B virus reinfection in liver transplant recipients.Intervirology, 2014, 57(3-4):196-201.
21. Jiang L, Yan L, Li B, et al.Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin.Am J Transplant, 2010, 10(8):1861-1869.
22. Marcellin P, Samuel D, Areias J, et al.Pretransplantation interferon treatment and recurrence of hepatitis B virus infection after liver transplantation for hepatitis B-related end-stage liver disease.Hepatology, 1994, 19(1):6-12.
23. Yang Y, Zhang Q, Cai CJ, et al.Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.Chin Med J (Engl), 2007, 120(16):1400-1403.
24. Ueda Y, Marusawa H, Kaido T, et al.Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation.Hepatol Res, 2013, 43(1):67-71.
25. Chen J, Yi L, Jia JD, et al.Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation:a systematic review.J Gastroenterol Hepatol, 2010, 25(5):872-879.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Analysis of Lamivudine Combined with Low-Dose Hepatitis B Immune Globulin to Prevent HBV Reinfection after Liver Transplantation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content